Short Interest in Surrozen, Inc. (NASDAQ:SRZN) Decreases By 21.6%

Surrozen, Inc. (NASDAQ:SRZN) was the recipient of a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 34,900 shares, a decline of 21.6% from the October 15th total of 44,500 shares. Approximately 1.5% of the company’s stock are short sold. Based on an average daily trading volume, of 18,300 shares, the short-interest ratio is currently 1.9 days.

Institutional Investors Weigh In On Surrozen

A number of institutional investors have recently modified their holdings of SRZN. CVI Holdings LLC bought a new stake in Surrozen in the second quarter valued at about $711,000. Stonepine Capital Management LLC bought a new stake in shares of Surrozen in the 2nd quarter valued at approximately $724,000. Nantahala Capital Management LLC acquired a new stake in shares of Surrozen during the 2nd quarter valued at approximately $2,050,000. Finally, Armistice Capital LLC bought a new position in Surrozen during the second quarter worth $2,080,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

Surrozen Stock Down 4.9 %

Shares of NASDAQ SRZN opened at $9.01 on Friday. Surrozen has a 1 year low of $5.61 and a 1 year high of $16.19. The stock’s 50-day simple moving average is $10.10 and its 200-day simple moving average is $9.77.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.77) by $2.33. The company had revenue of $10.00 million for the quarter. Research analysts forecast that Surrozen will post -7.16 earnings per share for the current fiscal year.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.